Home › Free Stock Grades › SUPN
Supernus Pharmaceuticals, Inc. (SUPN) Stock Grade
SUPN · Healthcare
B-
Market Cap
$2.6B
P/E Ratio
—
Revenue Growth (YoY)
+8.6%
Net Margin
-5.4%
Return on Equity
—
Dividend Yield
None
About Supernus Pharmaceuticals, Inc.'s fundamentals
Supernus Pharmaceuticals is a specialty pharmaceutical company with a $2.6 billion market capitalization that generated 8.6% year-over-year revenue growth in its latest period. Despite reporting a net loss with a negative 5.4% net margin, the company maintains positive free cash flow, indicating its operations are generating cash even as accounting losses persist. The company does not pay a dividend and is reinvesting resources into its business operations.